U.S. Markets closed

WuXi AppTec Co., Ltd. (603259.SS)

Shanghai - Shanghai Delayed Price. Currency in CNY
Add to watchlist
71.69-0.86 (-1.19%)
At close: 03:00PM CST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close72.55
Bid71.69 x 0
Ask71.70 x 0
Day's Range71.10 - 73.17
52 Week Range68.75 - 156.80
Avg. Volume27,055,907
Market Cap207.69B
Beta (5Y Monthly)0.70
PE Ratio (TTM)41.18
EPS (TTM)1.74
Earnings DateAug 11, 2022 - Aug 15, 2022
Forward Dividend & Yield0.52 (0.54%)
Ex-Dividend DateJun 09, 2022
1y Target Est158.47
  • PR Newswire

    WuXi STA Opens First High Potency Oral Drug Product Manufacturing Facility

    WuXi STA, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of its first high potency (HP) oral drug product manufacturing facility at its Wuxi city campus. This new facility marks a milestone for WuXi STA to further extend its drug product capacity and capabilities to meet the growing demand for HP drug candidate development and manufacturing services.

  • PR Newswire

    WuXi STA Opens a New Sterile Lipid Nanoparticle Formulation Facility to Enhance Global CRDMO Services for Customers

    WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its Wuxi city campus. Created in response to the increasing demand for complex injection dosage forms, this new facility marks the company's fast-growing parenteral formulation capabilities and is yet another opportunity to enable customers as they develop and deliver better medicines for patients.

  • PR Newswire

    WuXi STA Breaks Ground for New Pharmaceutical Manufacturing Facility in Middletown, Delaware

    WuXi STA, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the groundbreaking for its new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware. First announced in June 2021, this site will be WuXi STA's second facility in the United States, offering expanded capacity and greater flexibility to meet the needs of customers in the U.S. and around the world.